Snapshot from Jun 25, 2026 at 22:38 UTC. For live data and tracking: View Live
Events / Business / Dyne Therapeutics Completes ACHIEVE...
Business clinical trial enrollment

Dyne Therapeutics Completes ACHIEVE Trial Enrollment

Analysis based on 6 articles · First reported Jun 03, 2026 · Last updated Jun 03, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
Direct
Live prominence charts, article sentiment distribution, and event development timeline available on the NewsDesk Dashboard
Market Impact

The completion of enrollment in the ACHIEVE trial for zeleciment basivarsen by Dyne Therapeutics is a positive development for the biotechnology sector, particularly for companies developing treatments for rare diseases. This milestone could lead to increased investor confidence in Dyne Therapeutics and potentially other clinical-stage biopharmaceutical companies, as it signals progress towards regulatory approval and market entry for a novel therapy.

Biotechnology Pharmaceuticals
Event Summary

Dyne Therapeutics announced the completion of enrollment in the registrational expansion cohort of its Phase 1/2 ACHIEVE trial for zeleciment basivarsen (DYNE-101), an investigational therapeutic for Myotonic dystrophy type 1 (DM1). The cohort enrolled 71 participants, and topline data is expected in Q1 2027. This data will support a potential Biologics License Application (BLA) submission for U.S. Accelerated Approval in Q3 2027, with a potential U.S. launch in H1 2028. Zeleciment basivarsen has received Breakthrough Therapy, Orphan Drug, and Fast Track designations from the United States — Food and Drug Administration, and Orphan Drug designations from the European Union — European Medicines Agency and the Bangladesh — Ministry of Health and Family Welfare in Japan. The drug is designed to improve functional outcomes in individuals with DM1 by reducing toxic nuclear DMPK RNA.

Key Actions
100 Dyne Therapeutics completed enrollment
80 Dyne Therapeutics planned data release
70 United States — Food and Drug Administration granted designations Dyne Therapeutics
60 Dyne Therapeutics pursues approval pathways
40 European Union — European Medicines Agency granted designation Dyne Therapeutics
40 Bangladesh — Ministry of Health and Family Welfare granted designation Dyne Therapeutics
Entities Involved
stock
Dyne Therapeutics
Dyne Therapeutics announced the completion of enrollment in the registrational expansion cohort of its ACHIEVE trial for zeleciment basivarsen, a significant step towards potential market approval and commercialization of a treatment for Myotonic Dystrophy Type 1 (DM1). This milestone could positively impact the company's stock price and future revenue streams.
Importance 100 Sentiment 70
oth
Myotonic dystrophy type 1
Myotonic dystrophy type 1 (DM1) is the genetic neuromuscular disease that zeleciment basivarsen aims to treat. The successful progression of the ACHIEVE trial offers hope for patients suffering from this rare and severe condition.
Importance 80 Sentiment 0
govactor
United States — Food and Drug Administration
The United States — Food and Drug Administration (FDA) is the regulatory body responsible for granting Accelerated Approval and Priority Review for zeleciment basivarsen, which is crucial for its potential U.S. launch. The FDA has already granted Breakthrough Therapy, Orphan Drug, and Fast Track designations to zeleciment basivarsen.
Importance 70 Sentiment 0
cnt
United States
The United States is a key market for the potential launch of zeleciment basivarsen, with Dyne Therapeutics targeting U.S. Accelerated Approval and a U.S. launch in H1 2028.
Importance 50 Sentiment 0
govactor
European Union — European Medicines Agency
The European Union — European Medicines Agency (EMA) has granted Orphan Drug designation to zeleciment basivarsen, indicating Dyne Therapeutics' pursuit of approval pathways outside of the U.S.
Importance 30 Sentiment 0
govactor
Bangladesh — Ministry of Health and Family Welfare
The Bangladesh — Ministry of Health and Family Welfare (MHLW) in Japan has granted Orphan Drug designation to zeleciment basivarsen, supporting Dyne Therapeutics' efforts for international approval.
Importance 30 Sentiment 0
cnt
Japan
Japan is a country where Dyne Therapeutics is pursuing approval pathways for zeleciment basivarsen, as evidenced by the Orphan Drug designation from the Bangladesh — Ministry of Health and Family Welfare.
Importance 30 Sentiment 0
alliance
European Union
The European Union represents a significant market where Dyne Therapeutics is seeking approval for zeleciment basivarsen, supported by the Orphan Drug designation from the European Union — European Medicines Agency.
Importance 30 Sentiment 0
per
Doug Kerr
Doug Kerr, Chief Medical Officer of Dyne Therapeutics, provided commentary on the significance of completing enrollment in the ACHIEVE trial, highlighting the potential for zeleciment basivarsen as a best-in-class therapy.
Importance 20 Sentiment 0
NEWSDESK
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About NewsDesk

NewsDesk is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.newsdesk.dev.